Do analysts prefer XFOR or DTSQ?

X4 Pharmaceuticals presently has a consensus target price of $11.25, indicating a potential upside of 178.47%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe X4 Pharmaceuticals is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, XFOR or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than X4 Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio X4 Pharmaceuticals $15.85M 25.28 -$79.20M -$1.20 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Does the media refer more to XFOR or DTSQ?

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for DT Cloud Star Acquisition and 2 mentions for X4 Pharmaceuticals. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat X4 Pharmaceuticals' score of 0.94 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CAPR or DTSQ?

Capricor Therapeutics currently has a consensus price target of $29.15, indicating a potential upside of 203.96%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capricor Therapeutics 1 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.09 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, CAPR or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than Capricor Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capricor Therapeutics $22.27M 25.04 -$105.04M -$2.45 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is CAPR or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% DT Cloud Star Acquisition N/A N/A N/A

Does the media refer more to CAPR or DTSQ?

In the previous week, Capricor Therapeutics had 55 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 58 mentions for Capricor Therapeutics and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Capricor Therapeutics' score of 0.18 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, RCKT or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is RCKT or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -52.77% -44.92% DT Cloud Star Acquisition N/A N/A N/A

Does the media refer more to RCKT or DTSQ?

In the previous week, Rocket Pharmaceuticals and Rocket Pharmaceuticals both had 3 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 1.72 beat DT Cloud Star Acquisition's score of 1.07 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend LYEL or DTSQ?

Lyell Immunopharma currently has a consensus price target of $40.86, suggesting a potential upside of 181.19%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Lyell Immunopharma is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, LYEL or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than Lyell Immunopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lyell Immunopharma $40K 8,899.63 -$274.45M -$12.83 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Does the media favor LYEL or DTSQ?

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for DT Cloud Star Acquisition and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.77 beat DT Cloud Star Acquisition's score of 1.07 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DTSQ or UPB?

Upstream Bio has a consensus target price of $29.67, suggesting a potential upside of 343.45%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has stronger valuation & earnings, DTSQ or UPB?

DT Cloud Star Acquisition has higher earnings, but lower revenue than Upstream Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Upstream Bio $2.85M 128.57 -$143.44M -$2.90 N/A

Does the media refer more to DTSQ or UPB?

In the previous week, Upstream Bio had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 5 mentions for Upstream Bio and 3 mentions for DT Cloud Star Acquisition. Upstream Bio's average media sentiment score of 1.62 beat DT Cloud Star Acquisition's score of 1.07 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DT Cloud Star Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

DT Cloud Star Acquisition (DTSQ) Competitors

$11.34 0.00 (0.00%)

As of 08/28/2026

Compare

DTSQ vs. XFOR, CAPR, RCKT, LYEL, and UPB

Should you buy DT Cloud Star Acquisition stock or one of its competitors? DT Cloud Star Acquisition's main competitors and comparable companies include X4 Pharmaceuticals (XFOR), Capricor Therapeutics (CAPR), Rocket Pharmaceuticals (RCKT), Lyell Immunopharma (LYEL), and Upstream Bio (UPB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DT Cloud Star Acquisition compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 3 mentions for DT Cloud Star Acquisition and 2 mentions for X4 Pharmaceuticals. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat X4 Pharmaceuticals' score of 0.94 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DT Cloud Star Acquisition has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. DT Cloud Star Acquisition's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
DT Cloud Star Acquisition	N/A	N/A	N/A

72.0% of X4 Pharmaceuticals shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

X4 Pharmaceuticals presently has a consensus target price of $11.25, indicating a potential upside of 178.47%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe X4 Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

DT Cloud Star Acquisition has lower revenue, but higher earnings than X4 Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$15.85M	25.28	-$79.20M	-$1.20	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

X4 Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Summary

X4 Pharmaceuticals and DT Cloud Star Acquisition tied by winning 6 of the 12 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

In the previous week, Capricor Therapeutics had 55 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 58 mentions for Capricor Therapeutics and 3 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Capricor Therapeutics' score of 0.18 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Capricor Therapeutics currently has a consensus price target of $29.15, indicating a potential upside of 203.96%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.09
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Capricor Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

DT Cloud Star Acquisition has lower revenue, but higher earnings than Capricor Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	25.04	-$105.04M	-$2.45	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

DT Cloud Star Acquisition's return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
DT Cloud Star Acquisition	N/A	N/A	N/A

Summary

Capricor Therapeutics beats DT Cloud Star Acquisition on 7 of the 11 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

DT Cloud Star Acquisition's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
DT Cloud Star Acquisition	N/A	N/A	N/A

Rocket Pharmaceuticals has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Rocket Pharmaceuticals presently has a consensus price target of $8.57, indicating a potential upside of 122.06%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals and Rocket Pharmaceuticals both had 3 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 1.72 beat DT Cloud Star Acquisition's score of 1.07 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rocket Pharmaceuticals beats DT Cloud Star Acquisition on 7 of the 10 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Lyell Immunopharma?

Lyell Immunopharma (NASDAQ:LYEL) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

DT Cloud Star Acquisition has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. DT Cloud Star Acquisition's return on equity of 0.00% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
DT Cloud Star Acquisition	N/A	N/A	N/A

66.1% of Lyell Immunopharma shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lyell Immunopharma has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Lyell Immunopharma currently has a consensus price target of $40.86, suggesting a potential upside of 181.19%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Lyell Immunopharma is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

DT Cloud Star Acquisition has lower revenue, but higher earnings than Lyell Immunopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	8,899.63	-$274.45M	-$12.83	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for DT Cloud Star Acquisition and 2 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.77 beat DT Cloud Star Acquisition's score of 1.07 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lyell Immunopharma beats DT Cloud Star Acquisition on 7 of the 13 factors compared between the two stocks.

How does DT Cloud Star Acquisition compare to Upstream Bio?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

DT Cloud Star Acquisition has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. DT Cloud Star Acquisition's return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Upstream Bio	-4,955.67%	-48.40%	-46.57%

DT Cloud Star Acquisition has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Upstream Bio has a consensus target price of $29.67, suggesting a potential upside of 343.45%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

DT Cloud Star Acquisition has higher earnings, but lower revenue than Upstream Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Upstream Bio	$2.85M	128.57	-$143.44M	-$2.90	N/A

In the previous week, Upstream Bio had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 5 mentions for Upstream Bio and 3 mentions for DT Cloud Star Acquisition. Upstream Bio's average media sentiment score of 1.62 beat DT Cloud Star Acquisition's score of 1.07 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DT Cloud Star Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Upstream Bio beats DT Cloud Star Acquisition on 7 of the 10 factors compared between the two stocks.

Get DT Cloud Star Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTSQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTSQ vs. The Competition

Export

Metric	DT Cloud Star Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$100.94M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	N/A	11.62	273.16	25.45
Price / Sales	N/A	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	N/A	16.53	12.98	6.14
Net Income	N/A	-$22.80M	$3.48B	$348.86M
7 Day Performance	-0.53%	-0.31%	0.13%	-0.80%
1 Month Performance	-0.13%	9.80%	7.08%	4.13%
1 Year Performance	8.52%	55.66%	24.67%	15.17%

DT Cloud Star Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTSQ DT Cloud Star Acquisition	1.8846 of 5 stars	$11.34 flat	N/A	+8.5%	$100.94M	N/A	N/A	N/A	Positive News Short Interest Decrease
XFOR X4 Pharmaceuticals	2.1708 of 5 stars	$4.04 +0.2%	$11.25 +178.5%	+7.4%	$399.56M	$35.11M	N/A	80	Analyst Upgrade
CAPR Capricor Therapeutics	3.0634 of 5 stars	$6.29 -8.0%	$29.15 +363.4%	+52.7%	$397.38M	$22.27M	N/A	101	Trending News Analyst Upgrade Options Volume Gap Down
RCKT Rocket Pharmaceuticals	3.276 of 5 stars	$3.51 +0.9%	$8.57 +144.2%	+17.7%	$382.02M	N/A	N/A	240
LYEL Lyell Immunopharma	3.504 of 5 stars	$15.53 +1.2%	$40.86 +163.1%	+31.1%	$376.14M	$40K	N/A	270	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTSQ) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. XFOR, CAPR, RCKT, LYEL, and UPB

How does DT Cloud Star Acquisition compare to X4 Pharmaceuticals?

Summary

How does DT Cloud Star Acquisition compare to Capricor Therapeutics?

Summary

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Summary

How does DT Cloud Star Acquisition compare to Lyell Immunopharma?

Summary

How does DT Cloud Star Acquisition compare to Upstream Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DT Cloud Star Acquisition (DTSQ) Competitors

DTSQ vs. XFOR, CAPR, RCKT, LYEL, and UPB

How does DT Cloud Star Acquisition compare to X4 Pharmaceuticals?

Does the media refer more to XFOR or DTSQ?

Is XFOR or DTSQ more profitable?

Do insiders & institutionals have more ownership in XFOR or DTSQ?

Do analysts prefer XFOR or DTSQ?

Which has stronger valuation & earnings, XFOR or DTSQ?

Which has more volatility & risk, XFOR or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Capricor Therapeutics?

Does the media refer more to CAPR or DTSQ?

Do institutionals and insiders believe in CAPR or DTSQ?

Do analysts prefer CAPR or DTSQ?

Which has more volatility and risk, CAPR or DTSQ?

Which has higher earnings and valuation, CAPR or DTSQ?

Is CAPR or DTSQ more profitable?

Summary

How does DT Cloud Star Acquisition compare to Rocket Pharmaceuticals?

Is RCKT or DTSQ more profitable?

Which has more volatility and risk, RCKT or DTSQ?

Which has higher earnings and valuation, RCKT or DTSQ?

Do analysts prefer RCKT or DTSQ?

Do institutionals and insiders believe in RCKT or DTSQ?

Does the media refer more to RCKT or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Lyell Immunopharma?

Is LYEL or DTSQ more profitable?

Do institutionals & insiders have more ownership in LYEL or DTSQ?

Which has more risk and volatility, LYEL or DTSQ?

Do analysts recommend LYEL or DTSQ?

Which has preferable valuation & earnings, LYEL or DTSQ?

Does the media favor LYEL or DTSQ?

Summary

How does DT Cloud Star Acquisition compare to Upstream Bio?

Is DTSQ or UPB more profitable?

Which has more risk & volatility, DTSQ or UPB?

Do analysts prefer DTSQ or UPB?

Which has stronger valuation & earnings, DTSQ or UPB?

Does the media refer more to DTSQ or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTSQ vs. The Competition

DT Cloud Star Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools